• Incyte’s Opzelura (ruxolitinib) cream won a positive CHMP opinion for moderate atopic dermatitis in adults in the EU.
• The recommendation targets patients where topical corticosteroids or calcineurin inhibitors are inadequate or inappropriate.
• The European Commission is reviewing the opinion, which would make Opzelura the first steroid-free topical JAK option for this use in the EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202606260730BIZWIRE_USPR_____20260625_BW629388) on June 26, 2026, and is solely responsible for the information contained therein.